CPRX - Kapitalisasi marang volume dodolan Catalyst Corp
Catalyst Pharmaceuticals maintains dominance in the rare neuropathology niche through patents and lobbyist support, despite stringent FDA oversight. Growth is driven by the acquisition of new assets and the monetization of exclusive drugs. The current P/S trend clearly demonstrates the market valuation of capitalization to sales, where the indicator reaches 6.40. Logistics efficiency is ensured by the implementation of automated software and robotic packaging.
Rincian analitis perusahaan Catalyst Pharmaceuticals Inc (CPRX)
- rega lan prakiraan konsensus rega:
- statistik kapitalisasi pasar:
- informasi kapitalisasi buku:
- rincian struktur utang lan likuiditas bisnis:
Rasio Kabeh Utang marang Dana Pribadi Catalyst Pharmaceuticals|CPRX - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Catalyst Corp|CPRX - Utang perusahaan|Rasio utang marang aset resik Catalyst Pharmaceuticals Inc|CPRX - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Catalyst Pharmaceuticals|Rasio cepet catalystpharma.com
- informasi bathi lan kelipatan valuasi:
CPRX - Bathi resik|Bathi mangsa ngarep Catalyst Pharmaceuticals|CPRX - Pangali P/E|Rasio prakiraan rega marang bathi Catalyst Pharma|CPRX - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Catalyst Pharmaceuticals Inc|CPRX - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone patang kuartal pungkasan Catalyst Pharmaceuticals|CPRX - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan catalystpharma.com|CPRX - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Catalyst Pharmaceuticals
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:catalystpharma.com, CPRX
The P/S ratio compares the market value of Catalyst Pharmaceuticals (CPRX) to its sales volume, demonstrating how much investors are currently pricing in for each unit of revenue. By analyzing the price-to-sales trend, one can assess the premium for the company's drug monopoly status, which in the long term confirms the high market value of the biopharmaceutical business's stable cash flows.
Pesaing Catalyst Pharmaceuticals
Koefisien rega marang pendapatan biogen.com|Neurocrine Biosciences, Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan RGC (Regencell Bioscience Ltd)|AXSM: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ACAD (ACADIA Corp)|Xenon Pharmaceuticals (XENE) - Rasio rega marang pendapatan|Rasio rega marang dodolan VKTX (vikingtherapeutics.com)|SUPN (Supernus) - Multiplikator P/S|DNLI: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S HRMY|Multiplikator P/S Biohaven Corp (BHVN)|Rasio rega marang pendapatan Amylyx Pharmaceuticals AMLX|Rasio kapitalisasi pasar marang pendapatan TRVI|PRAX - Rasio rega marang pendapatan|Anavex (AVXL) - Kapitalisasi marang pendapatan|CBLL: Multiplikator P/S|Prothena Corp (PRTA) - Multiplikator P/S|ALEC (Alector Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan annexonbio.com (ANNX)|Multiplikator P/S OMER|NGNE - Rega marang dodolan|AC Immune Corp - Kapitalisasi marang pendapatan|Multiplikator P/S Voyager Corp VYGR|NMRA: Kapitalisasi marang pendapatan|scilexholding.com - Kapitalisasi marang volume dodolan|TVGN: Multiplikator P/S|ACOG - Koefisien rega marang pendapatan|CGTX (Cognition Therapeutics, Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan Inhibikase Pharma (IKT)|Multiplikator P/S SAVA|Multiplikator P/S assertiotx.com (ASRT)|Rasio rega marang pendapatan Coya Therapeutics COYA|VistaGen Therapeutics, Inc. - Rasio rega marang pendapatan|OVID - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Acumen Pharmaceuticals, Inc ABOS|CRVO: Multiplikator P/S|Kapitalisasi marang pendapatan Alterity Therapeutics Limited|Rasio rega marang pendapatan Clene Inc|PepGen Corp - Rasio rega marang dodolan|Rasio rega marang pendapatan Jupiter Neurosciences (JUNS)|RLMD (Relmada Corp) - Rasio kapitalisasi pasar marang pendapatan|Annovis Bio, Inc. - Kapitalisasi marang pendapatan|GRCE: Rasio kapitalisasi marang pendapatan|AIFF - Rasio rega marang pendapatan|KLTO (Klotho Neurosciences Inc) - Rasio kapitalisasi marang pendapatan|NRSN: Multiplikator P/S|Rega marang dodolan Reviva Pharmaceuticals, Inc. (RVPH)|Kapitalisasi marang pendapatan MTVA|Multiplikator P/S neuraxis.com|Rasio rega marang pendapatan Helius Medical (HSDT)|PASG (passagebio.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Neuphoria Therapeutics NEUP|Minerva (NERV) - Rega marang dodolan|Athira Pharma, Inc. - Multiplikator P/S|addextherapeutics.com (ADXN) - Kapitalisasi marang pendapatan|ALZN: Multiplikator P/S|Cyclerion Therapeutics, Inc. (CYCN) - Multiplikator P/S|Kapitalisasi marang pendapatan PTIX|KTTA (Pasithea) - Kapitalisasi marang volume dodolan|Multiplikator P/S CRGT|Multiplikator P/S avenuetx.com (ATXI)|Rasio rega marang pendapatan BrainStorm Cell Therapeutics BCLI|Cara Therapeutics Inc. - Rasio rega marang pendapatan|CHRO: Kapitalisasi marang pendapatan|Rega marang dodolan Eliem Therapeutics|intracellulartherapies.com (ITCI) - Rasio rega marang pendapatan|LBPH - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan MRNS|NKGN (NKGen Biotech Inc) - Kapitalisasi marang volume dodolan|Kapitalisasi marang pendapatan NRBO (NeuroBo)|SAGE (Sage Therapeutics Inc) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Synaptogenix, Inc. SNPX|TRVN (trevena.com) - Rasio rega marang dodolan|Vigil Neuro - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan WENA (anewmeds.com)|CERE: Multiplikator P/S
